Spero Therapeutics, Inc.
General ticker "SPRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $119.3M (TTM average)
Spero Therapeutics, Inc. follows the US Stock Market performance with the rate: 17.1%.
Estimated limits based on current volatility of 2.3%: low 2.78$, high 2.91$
Factors to consider:
- Total employees count: 46 (+12.2%) as of 2023
- Top business risk factors: Inability to establish sales force, Market competition, Operational and conduct risks, Climate change and natural disasters, Litigation risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.95$, 4.49$]
- 2026-12-31 to 2027-12-31 estimated range: [2.05$, 4.63$]
Financial Metrics affecting the SPRO estimates:
- Positive: with PPE of 19.3 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Positive: 7.54 < Operating profit margin, % of 9.45
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.06 > 6.06
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: Shareholder equity ratio, % of 85.64 > 64.29
- Negative: negative Industry operating income (median)
Short-term SPRO quotes
Long-term SPRO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $103.78MM | $47.98MM | $66.80MM |
| Operating Expenses | $82.30MM | $121.34MM | $60.49MM |
| Operating Income | $21.48MM | $-73.36MM | $6.31MM |
| Non-Operating Income | $3.92MM | $4.79MM | $2.52MM |
| R&D Expense | $51.44MM | $96.76MM | $38.47MM |
| Income(Loss) | $25.40MM | $-68.57MM | $8.83MM |
| Taxes | $2.60MM | $0.00MM | $0.26MM |
| Net Income(Loss)* | $22.81MM | $-68.57MM | $8.57MM |
| Stockholders Equity | $106.89MM | $46.12MM | $59.02MM |
| Assets | $182.39MM | $110.54MM | $68.92MM |
| Operating Cash Flow | $-32.99MM | $-23.44MM | $-12.62MM |
| Financing Cash Flow | $0.22MM | $0.00MM | $0.00MM |
| Earnings Per Share** | $0.43 | $-1.27 | $0.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.